Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth.

Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries. It has so far been molecularly defined mainly by alterations of the Wnt pathway. We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC. Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium. Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture. However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation. STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-negative variant impaired IL-6-driven proliferation. Blockade of STAT3 activation in CRC-derived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth.

[1]  Z. Xia,et al.  Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. , 2002, Blood.

[2]  E. Vellenga,et al.  Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. , 2000, Blood.

[3]  Jiayuh Lin,et al.  Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells , 2001, Oncogene.

[4]  K. Ozawa,et al.  Constitutive Activation of Stat1 and Stat3 in Primary Erythroleukemia Cells , 2002, International journal of hematology.

[5]  L. Kasturi,et al.  Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability , 2000, Oncogene.

[6]  Razelle Kurzrock,et al.  Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. , 2002, Cancer research.

[7]  G. Barnett,et al.  Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells , 2002, Oncogene.

[8]  A. Duval,et al.  Genetic instability in human mismatch repair deficient cancers. , 2002, Annales de genetique.

[9]  J. Bromberg.  Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.

[10]  R. Fodde,et al.  Apc modulates embryonic stem-cell differentiation by controlling the dosage of β-catenin signaling , 2002, Nature Genetics.

[11]  R. Fleming.  Colorectal cancer screening and follow-up. , 1998 .

[12]  R. Jove,et al.  Cooperative Regulation of Mcl-1 by Janus Kinase/STAT and Phosphatidylinositol 3-Kinase Contribute to Granulocyte-Macrophage Colony-Stimulating Factor-Delayed Apoptosis in Human Neutrophils1 , 2001, The Journal of Immunology.

[13]  C. Marth,et al.  Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  B. Groner,et al.  Homodimerization of Interleukin-4 Receptor α Chain Can Induce Intracellular Signaling* , 1996, The Journal of Biological Chemistry.

[15]  M. Oya,et al.  Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. , 2002, The Journal of urology.

[16]  K. Zatloukal,et al.  Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers , 2002, Oncogene.

[17]  M. Ittmann,et al.  Interleukin-6 is an autocrine growth factor in human prostate cancer. , 2001, The American journal of pathology.

[18]  Hua Yu,et al.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth , 2002, Oncogene.

[19]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Grandis,et al.  Differential function of STAT5 isoforms in head and neck cancer growth control , 2002, Oncogene.

[21]  S. Markowitz,et al.  Genetic and epigenetic alterations in colon cancer. , 2002, Annual review of genomics and human genetics.

[22]  M. LeBaron,et al.  Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells* , 2003, Journal of Biological Chemistry.

[23]  T. Eling,et al.  Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. , 1999, Carcinogenesis.

[24]  Li Li,et al.  Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines* , 2002, The Journal of Biological Chemistry.

[25]  P. Coletta,et al.  Truncated adenomatous polyposis coli (APC) tumour suppressor protein can undergo tyrosine phosphorylation. , 2000, European journal of cancer.

[26]  M. Masuda,et al.  Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.

[27]  Z. Estrov,et al.  CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY , 2002, British journal of haematology.

[28]  Karsten König,et al.  Modern laser scanning microscopy in biology, biotechnology and medicine. , 2003, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[29]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[30]  A. Schier,et al.  Stat3 Controls Cell Movements during Zebrafish Gastrulation. , 2002, Developmental cell.

[31]  P. Real,et al.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells , 2002, Oncogene.

[32]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[33]  G. Fuller,et al.  Constitutive activation of Stat3α in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2) , 2002, Oncogene.

[34]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[35]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[36]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[37]  B. Groner,et al.  The Interleukin-4 Receptor Activates STAT5 by a Mechanism That Relies upon Common γ-Chain* , 1998, The Journal of Biological Chemistry.

[38]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[39]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[40]  E. Keller,et al.  Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice , 2001, The Prostate.

[41]  R. Dhir,et al.  Stat3 activation in prostatic carcinomas , 2002, The Prostate.

[42]  G. Fontanini,et al.  Evaluation of telomerase in the development and progression of colon cancer. , 2002, International journal of molecular medicine.

[43]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[44]  U. Klingmüller,et al.  Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1 , 1999, Oncogene.

[45]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[46]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[47]  D. Levy,et al.  What does Stat3 do? , 2002, The Journal of clinical investigation.

[48]  Hans C Clevers,et al.  Molecular causes of colon cancer , 2002, European journal of clinical investigation.

[49]  J. Darnell,et al.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Mulligan,et al.  A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  G. Bommer,et al.  Wnt/Beta-Catenin/Tcf Signaling: A Critical Pathway in Gastrointestinal Tumorigenesis , 2002, Digestion.

[52]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.